. Author manuscript; available in PMC: 2022 May 17.

Published in final edited form as: Am Soc Clin Oncol Educ Book. 2022 Apr;42:1–15. doi: 10.1200/EDBK_351231

TABLE 3.

Clinical Activity Shown in Pivotal Clinical Trials by the Five Tyrosine Kinase Inhibitors With Regulatory Approval for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumor

	KIT/PDGFRA-Mutant GIST				PDGFRA D842V
Parameter	Imatinib	Sunitinib	Regorafenib	Ripretinib	Avapritinib
Reference	Demetri et al⁶⁶	Demetri et al⁶³	Demetri et al⁶⁷	Blay et al⁶⁸	Heinrich et al²³

Treatment line	First	Second	Third	Fourth or more	Any

ORR (%)	68.1	6.8	4.5	9.4	91.0

Stable disease at 12 weeks (%)	15.6	53.0	53.0	47.0	98.0

mPFS (mo)	24.0	5.6	4.8	6.3	34.0^*

Abbreviations: GIST, gastrointestinal stromal tumor; ORR, overall response rate; mPFS, median progression-free survival.

Updated mPFS from Jones et al.⁶⁹